The 2026 Issuance Wave: SK hynix, Bending Spoons, and the New Lockup Math

The US new-issue market is entering one of its most consequential stretches in years. After a prolonged post-2022 drought, the pipeline is filling with both mega-cap cross-border listings and mid-cap tech debuts, while a wave of secondary offerings and an unusually active buyback calendar pull capital in competing directions. Meanwhile, the lockup structures on 2026’s headline IPOs — Cerebras and SpaceX in particular — are rewriting the rules on when insider supply actually hits the tape.

Bending Spoons Prices Above Range as IPO Window Stays Open

Bending Spoons S.p.A. (Nasdaq: BSP) priced its IPO at $29 per share on June 30, above the marketed $26–$28 range, raising approximately $1.68 billion across 57.97 million shares. Of those, 34.4 million were primary shares offered by the company and 23.6 million were secondary shares from existing holders including Baillie Gifford — meaning roughly 41% of the deal was insider selling.{{cite:call0d897056}}

The Milan-based software acquirer operates a portfolio that includes AOL, Eventbrite, Vimeo, Evernote, WeTransfer, Brightcove, StreamYard, and others, serving over 500 million monthly active users and more than 9 million monthly paying customers as of March 2026. The company has completed more than 50 acquisitions to date, using a buy-transform-compound model that investors clearly rewarded with above-range pricing.{{cite:call0d897056}}

A syndicate of 15 bookrunners led by Goldman Sachs and J.P. Morgan underwrote the deal. Bending Spoons is expected to begin trading on Nasdaq on July 1.{{cite:call0d897056}}

Pricing above range on a deal that is 41% secondary is a meaningful demand signal. It indicates that institutional buyers were comfortable absorbing existing-holder supply at a premium — a contrast with the 2022–2023 IPO era, where above-range pricing was rare and secondary components were often slashed to get deals done.

SK hynix Targets Record $29.4B Nasdaq ADR Listing

The largest deal in the pipeline is SK hynix’s planned Nasdaq ADR listing under the symbol SKHY. The South Korean memory chipmaker filed with the SEC on June 24 to raise up to 45.45 trillion won (approximately $29.4 billion) through the offering of American Depositary Receipts, with each 10 ADRs representing one common share.{{cite:call5f3ac47d}}

At the top of the indicated range, the deal would surpass Alibaba’s $21.8 billion 2014 New York listing as the largest ADR offering on record. SK hynix has tentatively set July 10 for its trading debut, issuing 17.79 million new ADS representing approximately 2.5% of its Seoul-listed share base. Proceeds are earmarked for Korean fabrication capacity and EUV lithography equipment.{{cite:call5f3ac47d}}

The filing comes as SK hynix trades on the KOSPI under symbol 000660. The company is a dominant supplier of HBM (high-bandwidth memory) used in AI accelerators, making this listing a direct play on AI infrastructure demand for US investors who cannot easily access Korean shares.

The deal’s size will test market absorption capacity. A $29 billion offering dwarfs even the largest US IPOs of the post-2020 era and will likely draw capital from adjacent semiconductor and tech positions as portfolio managers make room.

This Week’s IPO Calendar at a Glance

Source: Renaissance Capital IPO Calendar, week of June 29, 2026.{{cite:call0d897056}}

Secondary Offerings: The Follow-On Pipeline

While IPOs dominate headlines, the follow-on market is equally active. Several meaningful secondaries priced in the final week of June:

• Vishay Intertechnology (VSH) filed a prospectus supplement for 15 million shares of common stock, with the last reported sale price at $56.35 on June 26. The offering priced on June 29.{{cite:call6493883c}}
• Definium Therapeutics (DFTX) closed an upsized $805 million public offering, including full exercise of the underwriters’ option to purchase additional shares — a signal of strong institutional demand for a late-stage biotech.{{cite:call6493883c}}
• uniQure (QURE) priced an upsized $225 million offering of 4,945,055 ordinary shares at $45.50 per share on June 23.{{cite:call6493883c}}
• Mama’s Creations (MAMA) priced a $100 million public offering of common stock on June 29.{{cite:call6493883c}}

The breadth of follow-ons — spanning semiconductors, biotech, gene therapy, and consumer foods — suggests that corporate treasurers across sectors are tapping a market that is receptive to dilutive issuance, not just IPO-hungry growth stories.

Staggered Lockups: The Cerebras and SpaceX Precedent

One of the most underappreciated market-structure developments of 2026 is the shift away from the traditional 180-day lockup toward staggered, performance-linked release schedules. Cerebras Systems (Nasdaq: CBRS) and SpaceX (Nasdaq: SPCX) are the two most prominent examples, and their structures are likely to become templates for future mega-IPOs.{{cite:call5f3ac47d}}

Cerebras: A Multi-Stage Unlock

Cerebras, which raised up to $6.4 billion in gross proceeds at $185 per share, does not have a single clean unlock date. According to its underwriting agreement and final prospectus:{{cite:call5f3ac47d}}

• Non-executive employees became eligible to sell 7.5% of eligible shares on the first trading day, and another 7.5% on the second day (triggered because the stock closed more than 33% above its IPO price on day one).
• Directors, officers, and pre-IPO investors can sell 15% of their shares after the company reports Q1 2026 earnings.
• Additional tranches unlock after Q2 2026 earnings and on fixed dates in August, September, and October.
• A final portion remains locked until the earlier of the post-Q3 earnings release or the 180-day outside date.

Over 60 million shares are released by the Q2‘26 earnings report.{{cite:call5f3ac47d}} The stock has round-tripped to its $185 IPO price as the market digested a guided gross-margin drop to 38–41% alongside the incoming lockup supply, despite a revenue beat and raised full-year guidance.{{cite:call5f3ac47d}} Cerebras carries a backlog of up to $24.6 billion, but nearly 80% of that is concentrated with OpenAI — a customer concentration risk that compounds the lockup overhang.{{cite:call5f3ac47d}}

SpaceX: Performance-Gated Releases

SpaceX’s lockup is similarly staged but with different mechanics:{{cite:call5f3ac47d}}

• Elon Musk and certain significant investors are subject to a 366-day lockup — double the traditional 180 days.
• Pre-IPO employees and general investors may receive up to 20% of eligible shares after SpaceX reports its first quarterly results as a public company.
• An additional 10% unlocks if the stock trades at least 30% above the IPO price during five of ten consecutive trading days before the earnings release date.
• Further staggered releases follow after Q2 earnings, but Musk and other top insiders are excluded from early-release provisions.

The stock trades approximately 15% above its IPO price ahead of Q2 earnings and the first lockup expiry.{{cite:call5f3ac47d}} Both Cerebras and SpaceX also bar holders from using derivatives, short sales, pledges, or swaps to synthetically hedge while shares are locked — closing the workaround loophole that existed in some earlier lockup agreements.{{cite:call5f3ac47d}}

Why This Matters for Liquidity

Staggered lockups serve a dual purpose. They reduce the risk of a single-day selling cliff that has historically crushed post-IPO stocks at the 180-day mark, and they give employees partial liquidity sooner, which can aid retention. But the trade-off is that they create multiple dates when new supply enters the market — each one a potential overhang. The Hong Kong-listed AI companies MiniMax-W (00100.HK) and Zhipu (2513.HK) have already demonstrated this dynamic: MiniMax shares plunged over 18% ahead of its first post-IPO lockup expiry on June 23, while Zhipu experienced a 30% intraday swing.{{cite:call5f3ac47d}}

Buyback Activity: The Counterweight

On the other side of the supply-demand equation, corporate buybacks remain robust:

• Accenture (ACN) increased its fiscal year 2026 share repurchase program by $2 billion, bringing the total planned repurchase to $7.5 billion — a 62% year-over-year increase. The company explicitly stated that leadership believes the share price does not reflect the company’s financial strength. All repurchases are to be completed by August 31, 2026.{{cite:call6493883c}}
• Visteon (VC) authorized an $800 million share repurchase program expiring December 31.{{cite:call6493883c}}
• Unilever (UL) completed its €1.5 billion 2026 share buyback.{{cite:call6493883c}}
• Intesa Sanpaolo launched a €2.3 billion buyback authorized by the ECB.{{cite:call6493883c}}

The buyback calendar provides a counterbalancing demand sink against the issuance wave, though buybacks tend to be pace-limited and spread over months, while IPO and follow-on supply arrives in concentrated bursts.

The Bigger Picture: Goldman’s $160B Call

Goldman Sachs has forecast that global IPO proceeds could quadruple to $160 billion in 2026, driven by rising stock prices, AI-sector enthusiasm, and a backlog of companies that deferred listings during the 2022–2024 drought.{{cite:call5f3ac47d}} Fidelity has similarly flagged 2026 as a potential record year, citing OpenAI, Anthropic, and Lambda (an AI infrastructure company reportedly planning an H2 2026 debut) as high-profile candidates still in the pipeline.{{cite:call5f3ac47d}}

The SK hynix listing alone would account for nearly 20% of that $160 billion target. Whether the market can absorb that size — and whether subsequent deals maintain above-range pricing — will be the defining question for the second half of the year.

What to Watch Next

1. SK hynix (SKHY) pricing and debut — Tentatively July 10. The final price range and first-day trading will signal whether the market can absorb a $29B ADR without displacing capital from other semiconductor names. Watch for flow rotation out of Micron, NVIDIA, and other memory/AI chip positions.

2. Bending Spoons (BSP) first-day performance — Trading begins July 1. Above-range pricing with a 41% secondary component is a strong demand signal, but first-day and first-week volume will reveal whether aftermarket buyers step in or whether selling shareholders front-run the float.

3. Cerebras (CBRS) Q2 2026 earnings and lockup release — The Q2 earnings report triggers the next major lockup tranche for directors, officers, and pre-IPO investors. With the stock sitting at its IPO price and a gross-margin guide that disappointed, the interaction between fundamentals and incoming share supply will be a real-time test of the staggered-lockup model.

4. SpaceX (SPCX) Q2 earnings and first lockup expiry — The first staggered release (up to 20% for employees/general investors, plus a potential 10% performance top-up) is tied to the first quarterly report. With the stock ~15% above IPO price, the 30%-above-IPO threshold for the additional tranche is the key level to monitor.

5. OpenAI and Anthropic filing timelines — If either company files an S-1 in Q3, it would anchor the next leg of the issuance wave and likely shift market attention away from the current crop of newly public names.

6. Follow-on cadence — The breadth of secondaries in late June (Vishay, Definium, uniQure, Mama’s Creations) suggests the follow-on window is wide open. A sustained pace would indicate that institutions are not yet saturated with new supply.

This article is based on publicly available filings, prospectus supplements, and market data as of July 1, 2026. It is for educational and research purposes only and does not constitute investment advice.